Ignite Creation Date:
2025-12-24 @ 6:56 PM
Ignite Modification Date:
2026-01-07 @ 4:43 AM
Study NCT ID:
NCT06142357
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-24
First Post:
2023-11-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12-29
Start Date Type:
ACTUAL
Primary Completion Date:
2027-08-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-08-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-11-16
First Submit QC Date:
None
Study First Post Date:
2023-11-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-23
Last Update Post Date:
2025-12-24
Last Update Post Date Type:
ACTUAL